Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation

Background: Lung cancer is the second most diagnosed cancer in the UK. Over 70% of lung cancers are non-small cell lung cancers (NSCLCs). Patients with stage III or IV NSCLC may be offered treatment to improve survival, disease control and quality of life. One-third of these patients receive further...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Janette Greenhalgh, Adrian Bagust, Angela Boland, Kerry Dwan, Sophie Beale, Juliet Hockenhull, Christine Proudlove, Yenal Dundar, Marty Richardson, Rumona Dickson, Anna Mullard, Ernie Marshall
Format: Artigo
Sprache:Inglês
Veröffentlicht: NIHR Journals Library 2015-06-01
Schriftenreihe:Health Technology Assessment
Schlagworte:
erlotinib
gefitinib
non-small cell lung cancer
systematic review
epidermal growth factor mutation
docetaxel
Online Zugang:https://doi.org/10.3310/hta19470
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge